Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the “Notes”) that the Notes are convertible, at the option of the holders (the “Conversion Option”) beginning on October 1, 2026, and ending at the close of business on December 31, 2026. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Notes being converted. Any determination regarding the convertibility of the Notes during future periods will be made in accordance with the terms of the Indenture governing the Notes.
- Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on October 1, 2026, the compensation committee of Apnimed’s board of directors granted 19 new non-executive employees non-qualified stock options to purchase an aggregate of 481,300 shares of the Company’s common stock under Apnimed’s 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $22.54, which is equal to Apnimed’s closing trading price on the grant date. One-fourth of the shares underlying each of the employee’s stock options will vest on the first anniversary of each employee’s start date and in equal monthly installments thereafter for the next three years, subject to such employee’s continued employment with the Company on such vesting dates.
- Outpost Technologies CorpExobiosphere to Become the First Commercial Customer of Outpost's New Space Factories, Bringing Microgravity Drug Discovery to Orbit and BackSpace biotech leader Exobiosphere will fly its Orbital High-Throughput System as the first customer module on Outpost's Space Factories platform — pairing repeatable microgravity access with reliable Earth return. LOS ANGELES, Oct. 2, 2026 -- Outpost Technologies Corporation...
- Rice UniversityRice Biotech Launch Pad invents 'living pharmacy' designed to produce therapeutics inside the bodyDurable implant to enter clinic in 2027 has multiple applications and represents new therapeutic approach that lasts full year — Biologic medicines can be powerful treatments for many diseases, but their cost can limit access. According to the U.S. Food...
- ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share CapitalTOULOUSE, France, October 02, 2026--Regulatory News: ABIONYX Pharma (Paris:ABNX):
- Klick Health Named MM+M Market Access Gold Agency of the YearNEW YORK & TORONTO, October 02, 2026--Klick Health took center stage throughout the evening at last night’s Medical Marketing + Media (MM+M) Awards, receiving the Market Access Gold Agency of the Year title plus nine campaign accolades, including five Gold trophies for "867-5309" (Cancer Support Community), "Project Inchstone" (Nestlé Compleat), and "MODDEN 26" (The Derek Sheely Foundation).
- Populus Health TechnologiesPopulus Health Technologies Announces New CROPRINCETON, N.J., October 02, 2026--Populus Health Technologies, a virtual care media and technology company, today announced the appointment of a new Chief Revenue Officer, Joe Catalano. As part of his new role, Catalano is responsible for planning and executing Populus’ sales and revenue strategy.
- Kaplan Fox Notifies Investors of Hims & Hers Health, Inc. (NYSE: HIMS) of a Securities Fraud Class Action Deadline on November 2, 2026Kaplan Fox announces a securities class action against Hims & Hers Health (NYSE: HIMS) for investors from Aug. 4, 2025 to July 29, 2026.
- Children's Minnesota to Launch Epic, Giving Families a More Connected Way to Manage Care with MyChartMINNEAPOLIS & ST. PAUL, Minn., October 02, 2026--Children’s Minnesota will go live with Epic, its new electronic health record, on Oct. 3, 2026, across its hospitals, clinics and specialty care sites.
- MarketsandMarketsClinical Trial Supplies Market worth $8.95 billion by 2031 - Exclusive Report by MarketsandMarkets™According to MarketsandMarkets™, the Clinical Trial Supplies Market is projected to reach USD 8.95 billion by 2031 from USD 5.60 billion in 2026, at a CAGR of 8.9% during the forecast period. Browse 420 market data Tables and 50 Figures...
- CRISPR Therapeutics AGCRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.
- SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.